Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection Tuesday September 5, 6:00 pm ET
NEW YORK, NY--(MARKET WIRE)--Sep 5, 2006 -- Amazon Biotech, Inc. (OTC BB:AMZB.OB - News) (Frankfurt:B2D.F - News) today announced that it has a Notice of Allowance from the United States Patent and Trademark Office, advising that Amazon's application for patent protection of its investigative drug named AMZ0026 has been approved. ADVERTISEMENT
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drug candidate and is currently approved by the FDA to undergo Phase I/II studies in humans. AMZ0026 has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, particularly with respect to elevation of CD4 levels in preliminary clinical case studies.
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are very pleased to receive the notice of allowance. We believe that this event significantly strengthens our intellectual property rights and increases our potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
